Looking back a few years, many of us remember when
Post# of 87941
(Total Views: 536)
Posted On: 09/13/2025 6:10:54 PM
Re: mikeyt1818 #87621
Looking back a few years, many of us remember when EuroMed, an Israeli med-tech firm, was floated as a possible reverse merger candidate with UNVC. The story was that EuroMed’s R&D in Israel on cannabis and CBD formulations could be brought into the U.S. through UNVC, using Dalton’s distribution and PBM connections. It made sense at the time: Israeli medical cannabis research is globally respected, and Dalton had openly mentioned Israel in relation to cannabis and healthcare innovation.
That never materialized, but the playbook is worth remembering.
Fast forward to today, and we see Dalton sitting on the Advisory Board of IR-Med (IRME), another Israeli med-tech company. IR-Med is OTCQB listed, based in Israel, and focused on AI-powered infrared diagnostic devices. On the surface it looks unrelated, but the parallels with EuroMed are striking: Israeli research base, U.S. OTC presence, and Dalton in the mix.
It raises the question: is IR-Med another bridge company, similar to how EuroMed was once viewed? Could it serve as part of a broader integration or even a reverse merger scenario tied into Dalton’s private ecosystem (HRI, Wellness, etc.)? Or is it simply an advisory role with no larger tie-in?
Adding to that, IR-Med has publicly said they are looking to uplist from OTCQB to a bigger exchange like Nasdaq or NYSE. If they are preparing an application now, the timing becomes important. One possible scenario is that IR-Med uplists on its own, then later merges with Dalton’s private companies, bringing in HRI or a consolidated Wellness Healthcare structure. Another possibility is a pre-uplist merger, where IR-Med absorbs Dalton’s assets first, then uplists as a larger combined entity. A rebrand to something like Wellness Healthcare or even UNIVEC could follow.
There’s also another angle. In many OTC reverse mergers, respected executives or advisors are placed on the board of a potential target company ahead of time as a breadcrumb. Dalton showing up on IR-Med’s Advisory Board looks similar to that pattern we’ve seen before in cannabis plays and other sectors. It doesn’t guarantee a merger, but it’s the kind of signal that often precedes one.
And we shouldn’t rule out that IR-Med could simply end up being a distribution partner with UNVC rather than a merger target. Dalton’s PBM and wellness network could serve as the commercialization pathway for IR-Med’s devices without any formal corporate combination.
What stands out is the consistency. Dalton has circled back to Israeli med-tech more than once. Whether cannabis (EuroMed) or AI/diagnostics (IR-Med), he seems to view Israel as a hub for the kind of innovations that can fit into his larger healthcare vision. If he still plans a “wraparound” model through UNVC or any public vehicle, IR-Med feels very much in line with that older EuroMed path.
No one knows if it leads to a merger, a distribution partnership, or nothing at all. But the pattern is there, and it’s worth watching closely—especially if IR-Med follows through on its uplist ambitions and Dalton’s network of companies eventually ties in.
That never materialized, but the playbook is worth remembering.
Fast forward to today, and we see Dalton sitting on the Advisory Board of IR-Med (IRME), another Israeli med-tech company. IR-Med is OTCQB listed, based in Israel, and focused on AI-powered infrared diagnostic devices. On the surface it looks unrelated, but the parallels with EuroMed are striking: Israeli research base, U.S. OTC presence, and Dalton in the mix.
It raises the question: is IR-Med another bridge company, similar to how EuroMed was once viewed? Could it serve as part of a broader integration or even a reverse merger scenario tied into Dalton’s private ecosystem (HRI, Wellness, etc.)? Or is it simply an advisory role with no larger tie-in?
Adding to that, IR-Med has publicly said they are looking to uplist from OTCQB to a bigger exchange like Nasdaq or NYSE. If they are preparing an application now, the timing becomes important. One possible scenario is that IR-Med uplists on its own, then later merges with Dalton’s private companies, bringing in HRI or a consolidated Wellness Healthcare structure. Another possibility is a pre-uplist merger, where IR-Med absorbs Dalton’s assets first, then uplists as a larger combined entity. A rebrand to something like Wellness Healthcare or even UNIVEC could follow.
There’s also another angle. In many OTC reverse mergers, respected executives or advisors are placed on the board of a potential target company ahead of time as a breadcrumb. Dalton showing up on IR-Med’s Advisory Board looks similar to that pattern we’ve seen before in cannabis plays and other sectors. It doesn’t guarantee a merger, but it’s the kind of signal that often precedes one.
And we shouldn’t rule out that IR-Med could simply end up being a distribution partner with UNVC rather than a merger target. Dalton’s PBM and wellness network could serve as the commercialization pathway for IR-Med’s devices without any formal corporate combination.
What stands out is the consistency. Dalton has circled back to Israeli med-tech more than once. Whether cannabis (EuroMed) or AI/diagnostics (IR-Med), he seems to view Israel as a hub for the kind of innovations that can fit into his larger healthcare vision. If he still plans a “wraparound” model through UNVC or any public vehicle, IR-Med feels very much in line with that older EuroMed path.
No one knows if it leads to a merger, a distribution partnership, or nothing at all. But the pattern is there, and it’s worth watching closely—especially if IR-Med follows through on its uplist ambitions and Dalton’s network of companies eventually ties in.
(4)
(0)